Syncope is a common clinical problem characterized by transient, spontaneously self-terminating loss of consciousness with complete and prompt recovery; the cause is insufficiency of cerebral oxygen/nutrient supply most often due to a transient fall of systemic arterial pressure to levels below those tolerated by cerebrovascular autoregulation. Careful and thorough evaluation of the cause of syncope is warranted in all patients. Determining that certain individuals are at "low mortality risk" is inadequate; syncope, although often benign from a mortality perspective, tends to recur, is associated with risk of physical injury, diminishes quality-of-life, and might lead to restriction from employment or avocation. However, the diagnostic evaluation and treatment of syncope is challenging for many reasons. First, syncope is only 1 of many causes of transient loss of consciousness. Second, the patient's symptoms are fleeting, and the patient is generally fully recovered when seen in the clinic; only infrequently are there helpful physical findings. Third, spontaneous events are often unwitnessed by medical professionals; consequently, the medical history of symptom events is usually a "second-hand" or "third-hand" story. Finally, there is often an excessive sense of diagnostic "urgency" that tends to result in a rush to undertake multiple poorly considered "diagnostic" testing procedures; a deliberate approach based on initial risk stratification is more likely to reap the dual rewards of a correct diagnosis and initiation of effective treatment in a cost-effective manner. (J Am Coll Cardiol 2009;53:1741-51)
The term "syncope" is derived from the Greek word "to cut short" or "interrupt"; its use as a descriptor of loss of consciousness has been traced back more than 600 years by editors of the Oxford English Dictionary. In this context, we can suppose that the link between the old Greek and current medical usage is the apparently temporary "interruption" of life's normal activities. However, in modern usage, "syncope" denotes a particular type of "interruption" in which: 1) loss of consciousness is temporary; 2) recovery is spontaneous, prompt, and complete; and 3) the cause is insufficiency of cerebral nutrient supply (1) . A transient fall of systemic arterial pressure to levels below cerebrovascular autoregulation requirements is most often to blame. Other mechanisms, such as abrupt hypoxemic events (e.g., aircraft decompression), are rare.
In practical terms, patients who present with transient loss of consciousness (TLOC) describe their symptoms with words such as "collapse," "fall," or "black-out." In these cases, "syncope" is only 1 possibility; a broad range of potential causes for real or presumed TLOC must be considered. Thus, epilepsy, concussions, metabolic disturbances, intoxications, and "syncope mimics" (e.g., psychogenic pseudo-syncope, cataplexy) are also contenders; each differs from syncope with respect to both pathophysiology and treatment.
This review provides an overview for cardiologists of current thought regarding treatment to prevent syncope recurrences. However, therapy cannot be examined in isolation; therefore, consideration is also given to a strategy for the TLOC/syncope evaluation.
Diagnostic Approach
Thorough evaluation of the cause of syncope is warranted in all patients. This is important, because syncope, although perhaps benign from a mortality perspective in most cases, is rarely a solitary event; recurrences, physical injury, diminished quality-of-life, and possible lifestyle limitations are real concerns (2, 3) . Consequently, the goal must be to determine the cause of syncope with sufficient confidence to provide a reliable assessment of prognosis, recurrence risk, and treatment options (4) .
Among the first questions to be addressed is whether to conduct the TLOC/syncope evaluation in-hospital or as an outpatient. Typical current practice patterns tend toward excessive in-hospital management. For instance, 1 recent report evaluated the frequency with which emergency de-partment (ED) physicians elected hospital stay for evaluation of presumed syncope (5) . Despite careful tutoring regarding European Society of Cardiology recommendations, there was a 25% inappropriate admission rate. Thus, many ED physicians remain concerned regarding the appropriateness of deferring syncope evaluations.
Potentially, greater use of "syncope management units" (SMUs), "rapid access blackout clinics" (6) , or "TLOC/syncope clinics" might reduce inappropriate hospital admissions (7, 8) . For example, in the SEEDS (Syncope Evaluation in the Emergency Department Study) trial patients were randomized to "standard care" or SMU after initial ED assessment (an ED-based SMU was used to manage intermediate-risk patients for up to 6 h) (8) . The frequency of presumptive diagnoses significantly increased from 10% in "standard care" patients to 67% with SMU evaluation, whereas both hospital admission frequency (98% to 43%) and total patient-hospital days (140 to 64 days) were less for SMU-managed patients. Furthermore, the SMU approach was more cost-efficient and equally as safe as the conventional strategy. Similarly, in the multicenter EGSYS-2 (Evaluation of Guidelines in Syncope Study 2) trial comparing "usual care" to guideline-based "standardized" care in the ED, the standardized group had a lower hospital stay rate (39% vs. 47%, p ϭ 0.001), shorter hospital stays (approximately 1 day less), fewer diagnostic tests (2.6 vs. 3.4, p ϭ 0.001), and an approximately 20% lower overall cost (7) . For EDs without an SMU, an observation unit similar to that used for "chest pain" assessment might prove useful.
Apart from more widespread application of SMUs, development of effective criteria for determining which patients require in-hospital evaluation would also reduce unnecessary admissions. However, despite many proposals (see Table 1 for selected examples) (1,8 -13) , none are perfect. For instance, the STePS (Short-Term Prognosis of Syncope) study suggested that an abnormal electrocardiogram (ECG), trauma, absence of warning, and male sex were markers of short-term (Ͻ10 days) adverse outcomes and therefore warranted hospital stay (9) . However, an accompanying editorial argued that the STePS study's positive predictive value for separating high-from low-risk patients was too small to be useful (10) . Similarly, attempts to validate other suggested stratification techniques have led to variable outcomes. For instance, the ROSE (Risk stratification Of Syncope in the Emergency department) study (14) found that clinical judgment was just as accurate as application of the San Francisco Rule (11) for reducing unneeded hospital admissions.
Our recommendations (Table 2) regarding the need for hospital stay of patients with presumed syncope are derived from the reports in Table 1 . In general, hospital admission is prudent if the suspected underlying problem is associated with high risk of early mortality or injury, the proposed treatment requires in-hospital care, or the affected individual is unable to care for himself or herself.
Syncope Classification and Diagnostic Tools
An accurate diagnosis is the essential foundation for effective treatment of syncope patients (Table 3) . However, despite a well-organized and thorough approach to establishing a syncope diagnosis (Fig. 1 ), often it is not possible to assign a single cause. Multiple comorbidities are common. Thus, individuals with heart disease might faint due to transient tachyarrhythmias, high-grade atrioventricular block, or overmedication. The physician should not too quickly accept an observed abnormality to be causal in a given individual.
The most valuable tools for establishing the basis of syncope are a careful medical history aided by eyewitness reports (1, 15, 16) and physical findings addressing the presence of structural heart disease (SHD). It has been reported that SHD independently predicts a cardiac cause of syncope with 95% sensitivity and 45% specificity (17) . Likewise, the absence of SHD excluded cardiac syncope in 97% of patients. Table 4 provides a summary of key findings that suggest a cardiac origin for syncope.
The 12-lead ECG and echocardiogram are essential elements of the initial syncope evaluation. Although it is rare that either provides a definitive diagnosis, they might facilitate choice of subsequent tests. For instance, ECG findings summarized in Table 5 or echocardiographic findings of unsuspected left ventricular dysfunction, dynamic ventricular outflow obstruction, or atrial myxoma/thrombus might provide valuable clues.
Extended-duration continuous ECG monitoring with either mobile cardiac outpatient telemetry (18) or an implantable loop recorder (ILR) (19 -22) has proved valuable for determining the cause(s) of syncope when events occur infrequently. For example, the RAST (Randomized Assessment of Syncope Trial) demonstrated that a primary ILR diagnostic strategy was twice as effective as a "conventional" work-up composed of 2 to 4 weeks of an external ECG loop recorder, provocative tilt-table testing, and electrophysiologic study (EPS) (19) . The EaSyAS (Eastbourne Syncope Assessment Study) came to a similar conclusion (20) . Both showed substantial ILR cost/diagnosis benefit.
Other tests, including tilt-table testing, EPS, and cardiac hemodynamic evaluation, should be chosen only when the initial evaluation supports their use (Fig. 1) . Indications for EPS in syncope patients and findings that might help to define a basis for syncope are summarized in Tables 6 and 7 . Neurological tests (e.g., electroencephalography and head computed tomography or magnetic resonance imaging) are almost never of value, absent concern regarding potential intracranial injury (e.g., subdural hematoma) that might have been sustained due to a fall.
Treatment of Specific Types of Syncope
Currently, treatment of syncope patients relies primarily on clinical experience and observational reports. The principal exceptions are vasovagal syncope and to a lesser degree orthostatic hypotension. Neurally mediated reflex syncopal syndromes. Patient education is the foundation of treatment of most neurally mediated syncope (NMS) syndromes. Patients must be informed that, although reflex faints are almost never life-threatening (1,23), they tend to recur (often in clusters), and injury can result if preventive measures are not taken seriously. Furthermore, patients might benefit by some understanding of basic pathophysiology and the importance of recognizing and responding to warning symptoms; such understanding not only reduces injury risk but also might ultimately enhance treatment compliance. In addition, it is important to identify and treat psychological and/or psychiatric factors that might contribute to exacerbating symptom susceptibility. In this regard, a high prevalence of minor psychiatric disorders has been reported in patients with vasovagal syncope (24, 25) .
Recurrent vasovagal fainters should learn techniques for aborting imminent attacks and reducing susceptibility to future attacks (e.g., physical maneuvers, liberalized salt intake, hydration). They should also be taught the value and possible risks of increased salt intake. In situational faints, it might be possible to ameliorate or avoid triggers. For instance, one might target cough suppression and smoking cessation in "cough syncope" and sitting while voiding in "micturition syncope." In some cases (e.g., syncope associated with fear of air flight), desensitization techniques might help.
Carotid sinus syndrome is a special form of NMS (1,26) that tends to occur in older individuals and predisposes Absence of evident SHD and a normal ECG History of recurrent syncope over many years Suspicion of "syncope mimic" (e.g., psychogenic pseudo-syncope) *The "low risk" group of patients is the largest subgroup of "syncope" patients, and averting an unnecessary hospital stay can have important cost-savings. It comprises primarily vasovagal, "situational," and most orthostatic (those without severe primary autonomic disease) faints. Syncope is of relatively "benign" nature in terms of mortality, but "falls risk" is a concern. Thus, virtually all vasovagal fainters and many orthostatic syncope patients (excluding perhaps elderly persons with excessive injury risk) can be discharged after careful discussion of the problem, instruction regarding basic preventative maneuvers, and follow-up arrangement. ECG ϭ electrocardiogram; SHD ϭ structural heart disease.
Classification of the Principal Causes of Syncope in Descending Order of Frequency
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them to falls and injury (26) . In such cases, although avoidance of tight collars, neckties, and abrupt neck movements is prudent advice, early initiation of cardiac pacing is usually recommended (1, 27, 28) . As alluded to earlier, physical counter-pressure maneuvers (PCM) are increasingly advocated to abort imminent NMS or orthostatic faints in patients who are aware of warning symptoms. Thus, squatting, arm-tensing, leg-crossing, and legcrossing with lower body muscle tensing have proved useful for averting an abrupt vasovagal reaction (29, 30) (Fig. 2) . In the PC-Trial (Physical Counterpressure Manoeuvres Trial), PCM reduced total burden and recurrence rate of syncopal events (31) . In brief, "usual" therapy plus PCM was compared with "usual" therapy alone in patients with recognizable warning symptoms. The syncope burden during follow-up was lower in PCM-trained patients versus control subjects; overall, 32% of PCM-trained and 51% of conventional arm patients experienced syncope recurrence (p Ͻ 0.005). Recurrence-free survival was better with PCM (39% relative risk reduction). Consequently, PCM should be part of the treatment strategy in patients with warning symptoms.
Strategies for reducing syncope recurrences in the longterm comprise: 1) physical techniques to improve orthostatic tolerance; 2) pharmacologic interventions to prevent Clinical Findings Suggesting a Cardiac Basis for Syncope: Primary Arrhythmia and/or Structural Origin Table 4 Clinical 
Figure 1 Initial Approach to the Evaluation of Suspected Syncope
Diagnostic pathway for evaluation of suspected syncope (see the Syncope Classification and Diagnostic Tools section for details). The approach advocated here is modified from that proposed in the European Society of Cardiology syncope guidelines. AECG ϭ ambulatory electrocardiogram; CSM ϭ carotid sinus massage; ECG ϭ electrocardiogram; Echo ϭ echocardiogram; EP ϭ electrophysiologic; ILR ϭ implantable loop recorder; Rx ϭ treatment; SHD ϭ structural heart disease.
1745
Syncope Therapy depletion of intravascular volume and/or enhance arterial and venous tone; and 3) cardiac pacing to avert bradycardia.
PHYSICAL TECHNIQUES. The goal of "tilt-training" (more accurately termed "standing-training") is to enhance neurovascular response to orthostatic stress (32) (Fig. 3) . Initially the "tilt-training" concept used repeated in-hospital exposure to postural stress by tilt-table tests until syncope was no longer inducible. However, this approach is impractical. Currently, the method entails home "standing-training" for progressively longer periods of time over 10 to 12 weeks. At the beginning, the recommended standing duration is 3 to 5 min twice daily; standing duration is then gradually lengthened every 3 to 4 days to as much as 30 to 40 min twice daily. Nonrandomized studies suggest that tilt-training reduces NMS susceptibility if undertaken consistently (33) (34) (35) . However, compliance is a limitation, and randomized observations have been less encouraging (36) . Further studies are needed.
PHARMACOTHERAPY.
A number of drugs, including "overthe-counter" remedies of uncertain composition and safety, are commonly prescribed for prevention of NMS. However, there are few randomized clinical trials, and consequently no agent, excepting perhaps midodrine, can be said to have proven effectiveness.
Syncope Due to Cardiac Arrhythmias: Indications for Electrophysiologic Study Volume expansion has been the foundation of medical therapy for both vasovagal faints and orthostatic syncope (discussed in later text). Conventional approaches to volume expansion entail increased dietary salt and electrolyte-rich sport drinks (although it is wise to avoid many high-caloric "sport" drinks) (37) . The primary safety concern is induction of hypertension. This is uncommon in younger patients but is a greater concern in older patients.
Among prescription drugs for volume expansion, fludrocortisone (a synthetic mineralocorticoid) is the most widely used, especially in younger patients (38) . Side effects include hypertension and hypokalemia. However, clinical evidence of fludrocortisone efficacy is weak. For instance, in adolescents, Scott et al. (39) demonstrated no benefit over atenolol in preventing recurrence of syncope in a randomized trial. Similarly, Salim and Di Sessa (40) found fludrocortisone to be less effective than placebo in preventing syncope or pre-syncope in children. A larger randomized controlled trial (RCT) with fludrocortisone in vasovagal syncope is ongoing (POST II [Second Prevention of Syncope Trial]) (41) .
Among other drug classes proposed for prevention of vasovagal faints, the beta-adrenoceptor antagonists (betablockers) were thought to reduce susceptibility by diminishing the impact of the adrenergic surge that commonly precedes and might be part of the trigger (15, (42) (43) (44) . However, supportive evidence is derived largely from observational reports and a single small RCT (45) . More recently a relatively large RCT (POST [Prevention of Syncope Trial]) showed no clear beta-blocker benefit in terms of syncope recurrence prevention (46) . In the POST trial, 208 patients with Ͼ2 syncopal events each were randomized to treatment with metoprolol or placebo. During a 1-year follow-up syncope recurrence was similar in both groups. However, somewhat surprisingly, older metoprolol-treated patients (age Ͼ42 years) seemed to show some benefit, albeit not statistically significant.
Vasoconstrictors and venoconstrictors have also been of interest in this setting. Etilephrine, a modest alpha-and beta-agonist, was studied in the VASIS (Vasovagal International Study) but did not prove effective (47) . Currently, midodrine is the principal vasoconstrictor for this indication. Midodrine is a pro-drug, metabolized in the liver to the active agent, desglymidodrine, which acts to constrict both arterial and venous beds, thus increasing peripheral blood pressure, improving venous return, and diminishing venous pooling. Midodrine has been most extensively studied in patients with orthostatic hypotension (48) but has also been shown to be effective in vasovagal syncope (49, 50) . Midodrine only infrequently causes hypertension, but it might precipitate urinary retention or urgency in older men and occasionally induces scalp "tingling" presumably due to piloerector muscle contraction. Methylphenidate has been proposed as an alternative for midodrine-intolerant patients (51); however, its value has not been established. Furthermore, unlike midodrine, methylphenidate crosses the blood brain barrier and can cause multiple adverse effects (e.g., agitation, movement disturbances, irritability).
Finally, several other drugs have been advocated but at best remain of uncertain effectiveness. Foremost among these are selective serotonin reuptake inhibitors (52) . It has been postulated that an abnormal hypersensitive serotonin response in the central nervous system contributes to triggering NMS; selective serotonin reuptake inhibitor pretreatment is thought to blunt this abnormal response. However, although 1 RCT showed reduced syncope recur- 
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Syncope Therapy rence in 30 patients taking active medication compared with placebo (53), a subsequent study showed no benefit (54).
Other agents-disopyramide, pure anticholinergics (e.g., scopolamine), and theophylline-have also been proposed, but the reported experience for any of these is small, uncontrolled, and currently unconvincing.
CARDIAC PACING. As noted earlier, cardiac pacing has long been considered an essential part of the treatment of carotid sinus syndrome (26, 27, 55, 56) . However, the role of pacing in patients with "refractory" vasovagal syncope is less certain. The proposed mode of benefit is thought to be prevention of severe bradycardia (cardio-inhibitory syncope Orthostatic syncope and related autonomic disturbances. Orthostatic syncope results from an excessive fall of systemic pressure (hypotension) triggered by postural change (e.g., supine or sitting to upright posture). In quantitative terms, clinically significant orthostatic hypotension is defined as a reduction of systolic blood pressure of Ն20 mm Hg and/or a diastolic fall of Ն10 mm Hg within 3 min of standing, regardless of whether symptoms occur. Orthostatic hypotension might be caused by: 1) impaired capacity of sympathetic nerves to increase vascular resistance due to primary nervous system disease or secondary to other diseases or drugs (or toxins) that adversely affect the autonomic nervous system; 2) relative volume depletion; 3) downward pooling of venous blood and a consequent reduction in stroke volume and cardiac output; or 4) impaired cardiac diastolic relaxation, especially of the aged or hypertrophied heart. Orthostatic syncope might be due specifically to: 1) primary autonomic neurological disturbance (e.g., pure autonomic failure, multiple system atrophy, Parkinson's disease); 2) drugs (e.g., vasodilators, diuretics); or 3) acquired disease (e.g., diabetes, alcohol, and so on) (62, 63) . Prevention is often difficult. When caused by a primary autonomic disease process, progress can often be made slowly if the patient is persistent with therapy, but complete return to "normal" is not a reasonable expectation. The best case is orthostatic syncope caused by nonessential drugs that can be eliminated.
Treatment of orthostatic syncope parallels the strategy discussed earlier for vasovagal and situational faints, with certain differences: 1) the duration of treatment is likely to be longer; 2) affected individuals are typically older and frailer, making PCM more difficult to employ; and 3) patients are more prone to supine hypertension.
Treatment should focus initially on education about factors that aggravate or provoke postural hypotension (Table 8 ). Thereafter, patients should be advised regarding maintenance of hydration (volume expanders are encouraged with careful follow-up to avoid excessive hypertension) as discussed in the reflex syncope section, PCM (Fig. 2) , and "tilt-training" (Fig. 3) . Furthermore, patients with autonomic failure should be advised to sleep with the head of the bed somewhat elevated (approximately 20 to 25 cm). Finally, vasoconstrictors such as midodrine (see the preceding text) might be introduced. However, fluctuating blood pressures and supine hypertension are often encountered. In such cases it is essential to try to tailor timing of therapy to support the arterial pressure during daytime and to prevent hypertension at night (while also minimizing risk of falling when affected individuals get out of bed in the middle of the night).
A special case is the patient with severe pure autonomic failure. In these individuals, bolus water intake, especially before rising from bed in the morning, might result in a valuable increase in blood pressure (64) . This technique might also be worth trying in other patients with postural hypotension in whom symptoms are often most troublesome in the morning (after prolonged absence of oral intake and increased supine renal filtration).
Other agents advocated for treatment of orthostatic hypotension in specialized circumstances include erythropoietin (65, 66) , clonidine (67), octreotide (68) , and desmopressin (69) . However, evidence supporting each of these is marginal. Cardiac arrhythmias as primary cause of syncope. Determining that a specific cardiac arrhythmia is responsible for syncope remains a diagnostic challenge. The initial evaluation might provide clues, but selected diagnostic tests are usually required. Long-term ECG monitoring is often warranted. In this regard, among wearable ECG event recorders, mobile cardiac outpatient telemetry devices have Common Factors That Increase Risk of Orthostatic Syncope Table 8 Common Factors That Increase Risk of Orthostatic Syncope been shown to be superior to conventional event recorders in syncope patients (18) . Additionally, the ISSUE study illustrated, in terms of implantable monitors, the diagnostic value of ILRs in syncope patients, in particular for those with underlying evidence of conduction system disease (70) or SHD (71) . In the former case, bradyarrhythmias tended to predominate, whereas in the latter, the detected arrhythmias were more heterogeneous. In some instances but not often, EPS is needed (Table 6 ). Apart from its diagnostic value, invasive EPS also offers the potential to cure certain arrhythmias by transvenous catheter ablation, a technique now available in most EPS laboratories. In the case of cardiac arrhythmias being the primary cause of syncope, treatment decisions are directed at the specific documented arrhythmia (1). Cardiac pacemakers are highly effective for bradyarrhythmias, whether due to underlying conduction system disease or, as is often the case in older patients, the effects of essential drug therapy (e.g., betablockers, anti-arrhythmic drugs). Tachyarrhythmic origins of syncope often lead to consideration of EPS mapping and ablation. For example, ablation is usually recommended as initial therapy for many supraventricular tachycardias and ventricular tachycardias of right or left ventricular outflow tract origin or due to bundle-branch re-entry. The effectiveness of ablation in paroxysmal atrial fibrillation causing syncope is less certain. In some cases, His bundle ablation with permanent pacing might be a valuable back-up option.
Absent the possibility of a curative ablation procedure, it is often necessary to use combinations of antiarrhythmic drugs along with implanted devices (pacemakers or implantable cardioverter-defibrillators [ICDs]). Thus, in patients with certain channelopathies (e.g., long QT syndrome, Brugada syndrome, short QT syndrome), the lifethreatening risk is often too great to rely on medications alone (e.g., beta-blockade in some long QT syndrome patients), and an ICD is recommended. However, ICDs alone might not prevent syncope, due to the time taken to diagnose the arrhythmia and initiate treatment. For instance, in an examination of data gleaned from SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial), rates of syncope did not differ between the 3 treatment arms (ICD, amiodarone, placebo) (72) . Structural cardiovascular and cardiopulmonary disease. Most often, syncope associated with SHD is secondary to either neurally mediated reflex mechanisms (e.g., acute myocardial ischemia) or primary arrhythmias, both of which have been discussed in the preceding text. In certain cases, however, hemodynamic studies reveal abnormalities of sufficient severity to indicate that SHD is directly responsible (e.g., severe aortic stenosis or mitral stenosis or obstructive HCM). In such instances, symptom prevention is best achieved by ameliorating the primary structural disturbance if possible. Thus, severe valvulopathies require surgery, whereas obstructive HCM can often be managed with drugs and possibly cardiac pacing (73) . In other circumstances, however, currently available interventions cannot provide adequate protection; pulmonary hypertension might be the most important example. Cerebrovascular syncope. Migraines due to vascular spasm might be the most important cause of syncope in this section; however, this mechanism must be rare, because it would require simultaneous multivessel involvement. More likely, the origin of faints in migraineurs might be related to an element of associated autonomic dysfunction (74) and in particular vasovagal events triggered by pain and nausea. In any case, the medical management includes use of betablockers and cranial/basilar artery vasoconstrictors such as sumatriptan (75) . Subclavian steal syndrome is another condition in this category that might cause faints, but these are very rare; its treatment requires either surgical or catheter-based intervention (76) .
Structural cerebrovascular disease might cause strokes and transient ischemic attacks but is almost never the cause of syncope. One very infrequent exception might be vertebrobasilar transient ischemic attacks, but these are usually accompanied by other posterior circulation symptoms such as vertigo. The treatment of transient ischemic attacks lies outside the boundaries of this review.
Conclusions
The evaluation and treatment of syncope is challenging. First, "syncope" is only one of many causes of TLOC. Second, symptoms are fleeting, and the patient is usually asymptomatic when seen in the clinic. Third, events are often unwitnessed; but even when witnessed, the stress of the moment might undermine reliability of the account. Finally, there is often an excessive sense of diagnostic "urgency"; this results in a rush to undertake multiple poorly considered "diagnostic" testing procedures. A deliberate approach based on initial risk stratification is more likely to reap the reward of a correct diagnosis.
Despite the difficulties, a thorough evaluation of the cause of syncope is warranted in all patients-not just in those deemed to be at high mortality risk. Conversely, the mere presence of an abnormal finding does not constitute a "diagnosis." The physician must carefully consider whether detected abnormalities are compatible with the clinical circumstances. The goal in every case should be to determine the cause with sufficient confidence to provide a reliable assessment of prognosis and treatment options.
